Vorinostat
This histone deacetylase (HDAC) inhibitor is used to treat cutaneous T-cell lymphoma (CTCL), a type of cancer affecting the skin, in patients whose disease has progressed or returned during or after two prior treatments. It works by blocking enzymes that regulate gene expression in cancer cells, promoting their death. Common side effects include fatigue, nausea, and blood clots, and patients need regular monitoring of blood counts and electrolytes.
分子量
264.3200 g/mol
LogP
1.90
TPSA
78.40 Ų
Lipinski 五规则
符合
治疗领域
作用机制
Provides essential ions for maintaining fluid balance, nerve conduction, muscle contraction, and acid-base homeostasis. Supplementation corrects electrolyte imbalances.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Provides essential ions for maintaining fluid balance, nerve conduction, muscle contraction, and acid-base homeostasis. Supplementation corrects electrolyte imbalances.
二维结构
Cite this structure
Embed this structure
SMILES
O=C(CCCCCCC(=O)Nc1ccccc1)NO
InChI
InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)
Molecular Formula
C14H20N2O3
HBD / HBA
3 / 3
可旋转键数
8
重原子数
19
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
This histone deacetylase (HDAC) inhibitor is used to treat cutaneous T-cell lymphoma (CTCL), a type of cancer affecting the skin, in patients whose disease has progressed or returned during or after two prior treatments. It works by blocking enzymes that regulate gene expression in cancer cells, promoting their death. Common side effects include fatigue, nausea, and blood clots, and patients need regular monitoring of blood counts and electrolytes.
Provides essential ions for maintaining fluid balance, nerve conduction, muscle contraction, and acid-base homeostasis. Supplementation corrects electrolyte imbalances.
Yes, Vorinostat is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL98. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5311. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="vorinostat"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/vorinostat/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/vorinostat/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/vorinostat/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="vorinostat"></drugfyi-drug>